older than 18 years (American Lung Association, 1998) . The staggering costs of asthma could be decreased. The health care community has made great progress in understanding the pathophysiology of asthma, greatly enhancing the ability to treat asthma with the advancement of treatment regimens.
Many factor s contribute to the increased asthma mortality rate. These include the overuse of beta adrenergic agonists, which gives prompt relief of the asthmatic condition and delays an individual seeking prompt health care attention and other medications or treatments that may be needed to prevent further exacerbations. Other factors include lack of adherence to prescribed treatment, low socioeconomic status, and the underuse, or the lack, of a primary care physician (Greenburg, 1999) . Additional reasons include the underuse of corticosteroids, inadequate client self management, and the inexperience of the clinician treating asthma.
PATHOPHYSIOLOGY
Asthma is clinically defined as a condition marked by recurrent, discrete episodes of reversible bronchial narrowing, separated by periods in which ventilation approaches normality. Many tissue changes occur within the bronchial airways during an asthmatic episode, which include spasm of the smooth muscle, mucosal edema, and hypersecretion of viscous mucus. Mucus , which gathers in the lumens of the bronchial tree, becomes difficult to mobilize due to the narrowing of the airway and the shedding of the ciliated bronchial epithelial cells normally serving as facilitators for the clearance of mucus. Individuals with asthma are unable to achieve normal flow rates during expiration, resulting in uneven lung aeration and a mismatch occurring between ventilation and pulmonary blood flow. During expiration, the diameter of the bronchioles becomes much more reduced than during inspiration. This is because of the increased pulmonary pressures compressing air within the alveoli during expiration. Therefore, the individual with asthma can inspire usually without difficulty but has difficulty expiring. Depending on the severity of the asthmatic episode, individuals may produce no symptoms or exhibit a range of difficulties from tracheal irritation to intolerable respiratory distress. The increased inflammation of the bronchial tree and the increased mucus production causes turbulence, which in effect, creates vibration of the mucus leading to audible wheezes during acute asthmatic attacks.
TYPES OF ASTHMA
The two most common forms of asthma are extrinsic and intrinsic. Extrinsic asthma comprises one third to one half of all the asthmatic cases reported (Copstead,1995) . Commonly known as allergic asthma, it generally affects children and young adults. Extrinsic asthma is related to specific antigens and is immunoglobulin (IgE) mediated. Irritants such as dust, pollens, and other allergens stimulate the IgE antibodies to attach themselves to the mast cells. This causes secretion of potent mediators including histamine, leukotrienes, prostoglandins, and kinins. These mediators cause smooth muscle contraction, eosinophil accumulation, mucus hypersecretion, and mucosal edema to occur within the bronchial tree (Copstead, 1995) .
Intrinsic asthma lacks demonstrable allergic factors and therefore is not considered to be IgE mediated. Intrinsic asthma usually develops in middle age. But many infants as well have been shown to have intrinsic asthma. Factors such as stress, pulmonary irritants, and exercise have been shown to precipitate an asthmatic attack (Copstead, 1995) .
Intrinsic asthma can be subdivided into further categories such as exercise induced asthma, drug induced asthma, and occupational asthma, which is considered to have both intrinsic and extrinsic properties. Exercise induced asthma can lead into bronchospasms within a matter of minutes after exercise begins. It is thought to be induced from water loss, heat loss, and the increased osmolarity of the lower respiratory tract, causing the mast cell to release chemical mediators and leading to constriction of the smooth muscle within the bronchioles (Copstead, 1995) .
Drug induced asthma has been shown to produce a wide variety of symptoms from rhinorrhea to respiratory arrest. These reactions are thought not to be IgE mediated and can occur from the ingestion of aspirin, tartrazine (yellow dye No.5 used to color pharmaceuticals), monosodium glucanate, and even hops in beer (Copstead, 1995) .
Asthma may be induced from aspirin and nonsteroidal antiinflammatory drugs (NSAID) in the aspirin intolerant person and may induce anaphylaxis, and even fatal asthmatic attacks. Attacks may occur suddenly without previous warning or can even be delayed as much as 12 hours. Clients with nasal polyps and asthma should refrain from the use of aspirin.
Asthma induced from aspirin and NSAID is believed to inhibit the conversion of arachidonic acid to prostoglandins. It is also speculated that aspirin shunts arachidionic acid breakdown to the leukotriene system (Copstead, 1995) . These lekotrienes are slowly released from the mast cells and possess powerful brochconstriction properties leading to severe and even fatal consequences. SEPTEMBER 2000, VOL.48, NO.9 Occupational asthma is thought to have many mechanisms that can trigger an asthma attack involving immediate classic IgE hypersensitivity, IgE delayed hypersensitivity, and the direct pharmacological effect on the airway receptors (Copstead, 1995) . Occupational asthma can be precipitated by metal fumes, salts, organic chemicals, drugs, isocyanates, engine exhaust, sulfur dioxide, textiles, fumes from plastic, and fluoride (Copstead, 1995) .
The host appears to experience some type of reaction no matter what the asthma inducing agents or the exact mechanisms may be. Symptoms are usually not encountered upon initial exposure, but develop after the initial exposure. Once the symptoms have begun with sensitivity to the agent, they will gradually become more severe and prolonged. Therefore, for many agents the mechanism is unknown and for others multiple mechanisms are suspected (Copstead, 1995) .
ASTHMA DIAGNOSIS
Asthma is an inflammatory disease affecting the airways of the bronchi in the lungs. The inflammation has little effect on inspiration, but plays havoc on expiration. The clinician can make a diagnosis of asthma by observing the expiratory effort of an individual who may be exhibiting an asthmatic episode.
The initial diagnosis of asthma is made with the use of a spirometer and a short acting inhaled Beta 2 agonist such as albuterol to determine if the airflow obstruction is partially reversible. The clinician must establish the presence of an airflow obstruction determined by the quotient of the FEV 1 (forced expiratory volume in 1 second) ratio divided by FVC (total volume of air exhaled). If the quotient is 80% or greater, no obstruction is present. Mild obstruction is considered to be a quotient between 70% and 80% and severe obstruction is a quotient of less than 50% (USDHHS, 1997).
The clinician may administer a bronchodilator such as albuterol and retest the client in 15 to 20 minutes. If the FEV 1 improves by 15% or more, the client is found to have a partially reversible bronchospasm leading to the diagnosis of asthma or asthmatic bronchitis (Copstead, 1995) . Older adults may need to take steroids for a period of 2 to 3 weeks to reduce inflammation before checking for the degree of reversibility obtained with a short acting Beta 2 agonist. The degree of reversibility achieved is helpful in determining the extent to which asthma therapy will be beneficial to the older adult.
MEDICATION TREATMENT OF ASTHMA
Medications such as short acting Beta 2 agonists and inhaled corticosteroids remain the mainstay in asthma treatment. Short acting inhaled Beta 2 agonists are known as "rescue" medications and include albuterol, considered to be the mainstay of Beta 2 agonists and metaproterenol. These rescue medications act as bronchodilators which expand the bronchioles of the airway.
Inhaled corticosteroids are medications used in conjunction with Beta 2 agonists in the treatment of asthma. These medications are used to decrease the inflammation in the bronchial airways, thereby decreas-
Stepwise Approach to Asthma Management*
Step 1: Mild Intermittent Asthma ing edema, mucus production, and plugging of the airways with thick viscid mucus. Corticosteroids include the most commonly used beclomethasone dipropuonate, triamcinolone acetonide (Azcort), and flunisolide (AeroBid). Oral corticosteroids, such as prednisone, can be used to treat acute exacerbation and severe, persistent asthma. New medications known as leukotriene agonists are used to manage chronic asthma by promoting bronchodilation and exhibiting antiinflammatory effects. They have also been shown to improve pulmonary function, reduce the amount of Beta 2 agonists needed, and decrease the number of attacks requiring oral steroids and visits to emergency departments (Kaiser, 1999) . These medications include zafirlukast, zileuton, and montelukast.
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Stepwise Approach to Asthma Management* (continued)
Step 3. Moderate Persistent Asthma 2. For control, use a long acting inhaled Beta 2 agonist (salmeterol 2 puffs q 12 hours) plus inhaled steroid beclomethasone (Vanceril) or flunisolide (AeroBid).
3. Sustained release theophylline or oral long acting Beta 2 agonists can be used.
Steroid tablets or syrup long term;
clinician should make a concerted effort to wean the oral steroids and attempt to control with a high dose corticosteroid inhaler.
• For adults and children older than 5 years.
Adapted from USDHHS (1997) .
STEPWISE APPROACH TO ASTHMA MANAGEMENT
In October 1997, the National Heart, Lung, and Blood Institute instituted a step care approach identifying starting points for treatment appropriate for the severity of asthma (USDHHS, 1997) . These starting points include: • Severe persistent. • Moderate persistent. • Mild persistent.
• Mild intermediate asthma.
The step approach was designed in an attempt to minimize exacerbations, reduce the need for hospitalization, minimize the use of Beta 2 agonists, minimize chronic symptoms, reduce limitations of physical activity, and acquire near normal PEF (highest rate of flow for 10 seconds or more at which air can be expelled from the lungs). See Sidebar on page 420 for description of the steps. The stepwise approach system is used as a guideline for clinical decision making. The clinician can start at any one of these appropriate steps in an attempt to control symptoms associated with asthma. Clinicians can use their best clinical judgment to step up to the next level to control symptoms or step down in progression of treatment if the client has sustained control of the condition for a 3 month period.
CLIENT SELF MANAGEMENT
Client education is the most important key to managing asthma. Effective education must include demonstrating the proper use of metered dose inhalers, identification of allergen triggers, and practice with a peak flow meter (see Sidebar on this page) to monitor the symptoms of asthma.
Clinicians prescribing metered dose inhalers need to instruct the client how to use the inhaler correctly. The proper way to use the inhaler is to (USDHHS, 1997): • Shake the inhaler vigorously and take the cap off. • Tilt the head back straight and breathe all the way out holding the inhaler 1 to 2 inches from the mouth. • Begin to take a slow breath and depress the inhaler once while taking a deep breath continuing to breathe in slowly for 3 to 5 seconds. • Hold breath for 10 seconds to allow the medicine to reach the lungs and then slowly exhale.
It is important to instruct clients to wait 1 minute between puffs of Beta 2 agonists so they may maximize their fullest dilatory effect on the bronchial tree. Other medications do not require waiting between puffs. If clients are not able to coordinate their breathing with their hand movement, a spacer can be used to administer metered dose inhalers in an appropriate fashion.
Individuals with asthma must make a concerted effort to avoid allergen triggers, which may exacerbate their condition. These triggers may include tobacco smoke, dust mites, animal dander, cockroaches, pollen, molds, strong odors, and sprays. All efforts must be undertaken to eliminate these triggers to control asthmatic exacerbations, help individuals maximize their usage of metered dose inhalers, and increase participation in physical activities without symptoms.
The peak flow meter is an essential tool used in monitoring individuals with moderate to severe asthma. The peak flow meter determines how well the client's asthmatic condition is controlled. Both clinicians and clients SEPTEMBER 2000, VOL.48, NO.9 
How To Use Your Peak Flow Meter

I. Starting Out: Find Your Personal Best Peak Flow Number
A. Asthma must be under good control for a 2 to 3 week period.
B. Take peak flow each day at the same time for 2 weeks.
1. Every morning (a.m.) upon waking.
2. Every night (p.m.) at bedtime (approximately 10 to 12 hours after the morning reading).
3. If you take an inhaled beta 2 agonist medicine, take your peak flow reading before taking that medicine or after using your medicine.
Reducing Asthma Morbidity and Mortality Cost Containment Strategies.
Kowalski, A.F. before going to bed, and before or after use of a Beta 2 agonist. The highest value achieved is considered to be the personal best.
After a personal best is established, peak flow zones can be used to dictate how to control asthma. These zones are divided into a green zone, yellow zone, and a red zone (correlated to the colors of a traffic light) and should be marked on the meter. The green zone lies between 80% and 100% of the personal best attempt with the flow meter. This signifies effective control of a client's condition. Medications prescribed should still be taken as directed to maintain this level of effective control. The yellow zone is considered to be 50% to 80% of the personal best attempt. This zone is the cautionary area, which helps to signify a worsening asthmatic condition.
1.
2.
3.
AAORN }ournaI2000; 48(9), 418-422. Asthma is the third leading cause of preventable hospitalization in the United States and has accounted for more than 3 million lost workdays.
Understanding the stepwise approach and the medications used to control asthma can reduce exacerbations which can contribute to reduction in costly emergency department visits.
Education is the key to controlling asthma. Encouraging effective daily peak flow monitoring, taking medications as directed, avoiding asthmatic triggers, and correctly using prescribed inhalers helps curb the spiraling costs of lost workdays.
Individuals with asthma must immediately add quick relief or rescue medications to their regimen. The yellow zone may also signify a need to increase other asthmatic medications as prescribed by the health care provider. The red zone lies below 50% of a personal best effort. This confirms a medical alert. Rescue medications must be used promptly and the health care provider notified immediately (see Sidebar on page 421).
CONCLUSION
Vigilance and self management are essential to controlling the exacerbation of asthma. Monitoring daily peak flow. taking medications as prescribed on a daily basis. avoiding asthmatic triggers, and correctly using prescribed inhalers will help individuals control asthma. Asthma should no longer be a disease of increasing mortality. Occupational health nurses and other clinicians can provide proper education. clear instructions, and work to motivate clients to control the potentially deadly effects of asthma. This education will ultimately help decrease health care costs associated with hospitalizations and lost work time that could be avoided with proper treatment and management of asthma.
